User Image Cart Icon 0 Search Image

Crosslink Breaker

  1. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker
  2. Role of the AGE crosslink breaker, alagebrium, as a renoprotective agent in diabetes
  3. Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension
  4. The effect of an advanced glycation end-product crosslink breaker and exercise training on vascular function in older individuals: a randomized factorial design trial
  5. Reversal of chaperone activity loss of glycated αA-crystallin by a crosslink breaker
  6. Reversal Of Lens Protein Crosslinking And Aggregation By A Novel crosslink breaker
  7. The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure
  8. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes
  9. The Effect of the AGE crosslink breaker ALT-711 on Accommodation, Outflow Facility, IOP, and Anterior Segment Morphology
  10. Advanced Glycation Endproduct “AGE” Accumulation in Elderly Hypertensive Canines: Correlation with Effects of AGE crosslink breaker
  11. The thiamine analogue and advanced glycation endproducts crosslink breaker ALT-711 does not interfere with transketolase activity
  12. Effects of alagebrium, an advanced glycation end‐product breaker, in patients with chronic heart failure: study design and baseline characteristics of the BENEFICIAL …
  13. An agent cleaving glucose-derived protein crosslinks in vitro and in vivo
  14. Effects of alagebrium, an advanced glycation endproduct breaker, on exercise tolerance and cardiac function in patients with chronic heart failure
  15. Therapeutic potential of breakers of advanced glycation end product–protein crosslinks
  16. Evaluation in vitro of AGE-crosslinks breaking ability of rosmarinic acid
  17. Advanced glycation end-products (AGEs): a novel therapeutic target for osteoporosis in patients with rheumatoid arthritis
  18. … and clinical improvements among patients with advanced heart failure treated with Alagebrium (a novel oral advanced glycation end-product crosslink breaker)
  19. Current therapeutic interventions in the glycation pathway: evidence from clinical studies
  20. The Effect of Advanced Glycation End Products (AGE) breaker, Alagebrium on the Cardiac Structural and Functional Change in Type I Diabetic Rat Model
  21. Evaluate the effect of Withania somnifera methanolic extracts as in-vitro antiglycating agents
  22. C16, a novel advanced glycation endproduct breaker, restores cardiovascular dysfunction in experimental diabetic rats1
  23. The breakdown of pre‐existing advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes
  24. Effects of Advanced Glycation End-Product Inhibition and Protein Cross-Link Breaking in Diabetic Rats
  25. The putative antiglycation agent phenacylthiazolium bromide suppresses cellular triosephosphate accumulation in model hyperglycaemia in vitro by stimulating the …
  26. Alagebrium attenuates methylglyoxal induced oxidative stress and AGE formation in H9C2 cardiac myocytes
  27. Pharmacological therapy of age-related macular degeneration based on etiopathogenesis
  28. Effect of the AGE-breaker alagebrium on plasma and tissue advanced glycation end-products and sRAGE
  29. Extracellular glycation crosslinks: prospects for removal
  30. Factors influencing crosslink formation in muscle tissue
  31. Effect of advanced glycation end‐products (AGE) lowering drug ALT‐711 on biochemical, vascular, and bone parameters in a rat model of CKD‐MBD
  32. Advanced glycation endproduct crosslinking in the cardiovascular system: potential therapeutic target for cardiovascular disease
  33. Effects of alagebrium, an AGE breaker, on exercise tolerance and cardiac function in patients with chronic heart failure
  34. Effect of non-antihypertensive drugs on endothelial function in hypertensive subjects evaluated by flow-mediated vasodilation
  35. Treating diastolic heart failure with AGE crosslink breakers: thinking outside the heart failure box
  36. Novel therapies for diabetic kidney disease: storied past and forward paths
  37. Aldose reductase inhibition ameliorates the detrimental effect of estrogen replacement therapy on neuropathology in diabetic rats subjected to transient forebrain …
  38. Novel in Vitro Modification of Bone for an Allograft with Improved Toughness Osteoconductivity
  39. Gut microbiome-derived metabolite trimethylamine N-oxide induces aortic stiffening and increases systolic blood pressure with aging in mice and humans
  40. Effect of cysteine on methylglyoxal-induced renal damage in mesangial cells
  41. Advanced glycation endproduct induces ROS accumulation, apoptosis, MAP kinase activation and nuclear O-GlcNAcylation in human cardiac myocytes
  42. Cardiovascular Complications
  43. Staphylococcus aureus Biofilm Inhibiting Activity of Advanced Glycation Endproduct crosslink Breaking and Glycation Inhibiting Compounds
  44. crosslink breakers: a new approach to cardiovascular therapy
  45. Alagebrium: benefit on peripheral arteries
  46. Advanced glycation end-products in chronic heart failure
  47. The effect of advanced glycation end products (AGE) breaker, alagebrium on the cardiac structural and functional change in type I diabetic rat model
  48. Phenotypic transitions and fibrosis in diabetic nephropathy
  49. Heart-Kidney Connection: Myocardial Infarction Induces Renal Cortical and Medullary Fibrosis and Activation of Renal Molecular Remodeling in the Absence of Heart …
  50. Effect of the age cross-link breaker alagebrium on anterior segment physiology, morphology, and ocular age and rage
  51. Diversity in management of heart failure patients
  52. Uncoupled Nitric Oxide Synthase Leads to Diastolic Dysfunction Irrespective of Blood Pressure
  53. The Effect of Breaking Advanced Glycation End-Products, With or Without Exercise Training on the Cardiovascular Effects of Aging
  54. Skin autofluorescence, 5-year mortality, and cardiovascular events in peripheral arterial disease: all that glitters is surely not gold
  55. Getting better without AGE: new insights into the diabetic heart
  56. The role of collagen crosslinks in ageing and diabetes-the good, the bad, and the ugly
  57. Vascular aging: from molecular mechanism to clinical significance
  58. Cleaving effect of pomegranate (Punica granatum) extract on crosslink derived from advanced glycation endproducts
  59. Alagebrium in combination with exercise ameliorates age-associated ventricular and vascular stiffness
  60. Pyridoxal phosphate prevents progression of diabetic nephropathy
  61. The AGE of the matrix: chemistry, consequence and cure
  62. Dyssynchrony in Regional Left Ventricular Systolic Function in Light Chain Amyloidosis: Assessment Using Novel 4D Echocardiography
  63. Inhibitors of the Maillard reaction and AGE breakers as therapeutics for multiple diseases
  64. Cardiovascular and renal effects of a collagen cross-link breaker (ALT 711) in adult and aged spontaneously hypertensive rats
  65. Hyperglycemia and arterial stiffness: the atherosclerosis risk in the communities study
  66. Fracturing Carbonate Reservoirs: Acidising Fracturing or Fracturing with Proppants?
  67. Alagebrium chloride protects the heart against oxidative stress in aging rats
  68. The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy
  69. Arterial stiffness: a focus on vascular calcification and its link to bone mineralization
  70. Advanced glycation end products, oxidative stress and diabetic nephropathy
  71. Diabetic nephropathy: important pathophysiologic mechanisms
  72. Advanced glycation end products in health and disease
  73. EFFECT OF AGE ON SHEAR MODULUS OF SKELTAL MUSCLE
  74. A review on prevention of glycation of proteins: Potential therapeutic substances to mitigate the severity of diabetes complications
  75. Targeting advanced glycation with pharmaceutical agents: where are we now?
  76. Inhibition of renin-angiotensin system and advanced glycation end products formation: a promising therapeutic approach targeting on cardiovascular diseases
  77. Therapeutic interventions for advanced glycation-end products and its receptor-mediated cardiovascular disease
  78. The inhibition of advanced glycation end products by carnosine and other natural dipeptides to reduce diabetic and age‐related complications
  79. The role of AGE/RAGE signaling in diabetes-mediated vascular calcification
  80. AGE-breaker ALT-711 plus insulin could restore erectile function in streptozocin-induced type 1 diabetic rats
  81. Advanced glycation/glycoxidation endproduct carboxymethyl-lysine and incidence of coronary heart disease and stroke in older adults
  82. Assessing the potential of carboxylic acids as inhibitors of glycation
  83. N-phenacylthiazolium bromide reduces bone fragility induced by nonenzymatic glycation
  84. Repairing extracellular aging and glycation
  85. Potential new therapeutic agents for diabetic kidney disease
  86. Serum carboxymethyl–lysine, an advanced glycation end product, is associated with increased aortic pulse wave velocity in adults
  87. Diabetes and advanced glycation endproducts
  88. Glycation end-product cross-link breaker reduces collagen and improves cardiac function in aging diabetic heart
  89. Causes and characteristics of diabetic cardiomyopathy
  90. Advanced glycation and retinal pathology during diabetes
  91. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept
  92. Pimagedine: a novel therapy for diabetic nephropathy
  93. Blockade of diabetic vascular injury by controlling of AGE-RAGE system
  94. Advanced glycation end-product cross-link breakers: a novel approach to cardiovascular pathologies related to the aging process
  95. Alagebrium (ALT-711) Attenuates Gastric Aspiration Induced Pulmonary Inflammatory Response In Mice Fed With High AGE Diet
  96. The putative role of methylglyoxal in arterial stiffening: A review
  97. Receptor for advanced glycation end products (RAGE): novel biomarker and therapeutic target for atrial fibrillation
  98. The effects of advanced glycation end products (AGEs) on dermal wound healing and scar formation: a systematic review
  99. Advanced glycation end-products and arterial stiffness in hypertension
  100. Role of AGEs in diabetic nephropathy
  101. TRC4186, a novel AGE-breaker, improves diabetic cardiomyopathy and nephropathy in Ob-ZSF1 model of type 2 diabetes
  102. The breakdown of preformed advanced glycation end products reverses erectile dysfunction in streptozotocin‐induced diabetic rats: Preventive versus curative …
  103. Therapeutic potential of AGE inhibitors and breakers of AGE protein cross-links
  104. Advanced glycation end products in renal failure: an overview
  105. Causative or associative: A critical review of the role of advanced glycation end-products in bone fragility
  106. Nitric oxide, oxidative excess, and vascular complications of diabetes mellitus
  107. Advanced glycation end products and diabetic complications
  108. Hydralazine inhibits rapid acrolein-induced protein oligomerization: role of aldehyde scavenging and adduct trapping in cross-link blocking and cytoprotection
  109. Republished paper: arterial stiffness in chronic kidney disease: causes and consequences
  110. The multiple faces of RAGE–opportunities for therapeutic intervention in aging and chronic disease
  111. Large artery stiffness and brain health: Insights from animal models
  112. Effect of Korean red ginseng on arterial stiffness in subjects with hypertension
  113. Therapeutic interventions in the glyc (oxid) ation pathway
  114. Novel therapeutics for diabetic micro-and macrovascular complications
  115. Heart failure with preserved ejection fraction: emerging drug strategies
  116. Effect of Cirsium japonicum Flower Extract on Skin Aging Induced by Glycation
  117. Advanced glycation of apolipoprotein AI impairs its anti-atherogenic properties
  118. The role of advanced glycation end-products and their receptor on outcome in heart failure patients with preserved and reduced ejection fraction
  119. Study on the nonenzymatic glycation of nucleosides/nucleotides and proteins with sugars: An in vitro investigation of advanced glycation endproducts (AGEs) …
  120. AGEs impair Kv channel-mediated vasodilation of coronary arteries by activating the NF-κB signaling pathway in ZDF rats
  121. Protein glycation during aging and in cardiovascular disease
  122. Methylglyoxal impairs glucose metabolism and leads to energy depletion in neuronal cells—protection by carbonyl scavengers
  123. The role of collagen metabolism in CKD-associated arterial senescence: underestimated and underappreciated
  124. Protein crosslinking by the maillard reaction with ascorbic acid and glucose
  125. Advanced glycation endproducts and plaque instability: a link beyond diabetes
  126. An update on advanced glycation endproducts and atherosclerosis
  127. Skin autofluorescence, a marker for advanced glycation end product accumulation, is associated with arterial stiffness in patients with end-stage renal disease
  128. Advanced glycation endproducts (AGEs): pharmacological inhibition in diabetes
  129. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis
  130. AGEs and cardiovascular diseases in patients with end-stage renal diseases
  131. Targeting advanced glycation endproducts and mitochondrial dysfunction in cardiovascular disease
  132. Glucose, Glycation, and RAGE: Implications for Amplification of Cellular Dysfunction in Diabetic Nephropath: y
  133. The role of advanced glycation in the pathogenesis of diabetic retinopathy
  134. Does accumulation of advanced glycation end products contribute to the aging phenotype?
  135. Potential clinical utility of advanced glycation end product cross-link breakers in age-and diabetes-associated disorders
  136. Emerging therapies for chronic kidney disease: what is their role?
  137. Effects of alagebrium, an AGE breaker, in patients with chronic heart failure: study design and baseline characteristics of the BENEFICIAL trial
  138. Low adipocyte IRS-1 protein expression is associated with an increased arterial stiffness in non-diabetic males
  139. Advanced glycation end products and schizophrenia: A systematic review
  140. Pharmacological control of receptor of advanced glycation end-products and its biological effects in psoriasis
  141. Physical properties of anionic poly (ε-caprolactam) synthesized in the presence of calcium chloride
  142. AGE-RAGE axis blockade in diabetic nephropathy: current status and future directions
  143. Association of pulse wave velocity with vascular and valvular calcification in hemodialysis patients
  144. Collagen cross-link breakers: a beginning of a new era in the treatment of cardiovascular changes associated with aging, diabetes, and hypertension
  145. Advanced glycation end products and their circulating receptors and level of kidney function in older community-dwelling women
  146. Methylglyoxal and advanced glycation endproducts: new therapeutic horizons?
  147. Functional effects of alagebrium (alt-711)–isolated rat carotid artery
  148. The advanced glycation end product-lowering agent ALT-711 is a low-affinity inhibitor of thiamine diphosphokinase
  149. Advanced glycation: an important pathological event in diabetic and age related ocular disease
  150. Role of advanced glycation end products in hypertension and atherosclerosis: therapeutic implications
  151. Oxidative stress and aging: is methylglyoxal the hidden enemy?
  152. Phase I clinical studies of the advanced glycation end-product (AGE)-breaker TRC4186: safety, tolerability and pharmacokinetics in healthy subjects
  153. Regulation of advanced glycation end product (AGE)-receptor (RAGE) system by PPAR-gamma agonists and its implication in cardiovascular disease
  154. Multi-User Publishing in the Web: DReSS, A Document Repository Service Station
  155. Current perspectives in diastolic dysfunction and diastolic heart failure
  156. Methylglyoxal displays colorectal cancer-promoting properties in the murine models of azoxymethane and CT26 isografts
  157. Aldose reductase pathway inhibition improved vascular and C-fiber functions, allowing for pressure-induced vasodilation restoration during severe diabetic …
  158. Modulation of α‐crystallin chaperone activity: A target to prevent or delay cataract?
  159. Impaired left ventricular relaxation in type 2 diabetic rats is related to myocardial accumulation of Nɛ‐(carboxymethyl) lysine
  160. Optimal treatment of hypertension with diastolic heart failure
  161. Agents in development for the treatment of diabetic nephropathy
  162. How important and how treatable is vascular stiffness as a cardiovascular risk factor in renal failure?
  163. Nephrin loss in experimental diabetic nephropathy is prevented by deletion of protein kinase C alpha signaling in-vivo
  164. Alagebrium and complications of diabetes mellitus
  165. Advanced glycation endproducts and osteoarthritis
  166. Role of advanced glycation end products in diabetic neuropathy
  167. Do diabetes and hypertension interact to accelerate vascular ageing?
  168. Drug therapy for the cardiac complications of diabetes
  169. Vascular mechanics in decellularized aortas and coronary resistance microvessels in type 2 diabetic db/db mice
  170. Molecular determinants of heart failure with normal left ventricular ejection fraction
  171. Effects of cross-link breakers, glycation inhibitors and insulin sensitisers on HDL function and the non-enzymatic glycation of apolipoprotein AI
  172. Quinapril treatment abolishes diabetes-associated atherosclerosis in RAGE/apolipoprotein E double knockout mice
  173. Impact of age and hyperglycemia on the mechanical behavior of intact human coronary arteries: an ex vivo intravascular ultrasound study
  174. Preferential stiffening of central over peripheral arteries in type 2 diabetes
  175. A short-term admission improved brachial–ankle pulse wave velocity in type 2 diabetic patients
  176. New drugs under development for cardiovascular prevention
  177. The breakdown of preformed peritoneal advanced glycation end products by intraperitoneal alagebrium
  178. Arterial stiffness and wave reflections in relation to plasma advanced glycation end products in a Chinese population
  179. Cellular mechanisms and consequences of glycation in atherosclerosis and obesity
  180. Karl D. Nolph state of the art lecture: feasible and future options for salvation of the peritoneal membrane
  181. Heart Failure with Preserved Ejection Fraction
  182. Glycation: Receptor for Advanced Glycation Endproducts and Diabetic Nephropathy
  183. Advanced glycation end products accumulate in vascular smooth muscle and modify vascular but not ventricular properties in elderly hypertensive canines
  184. Arterial stiffening: Causes and consequences
  185. Heart failure and diabetes mellitus: epidemiology and management of an alarming association
  186. Discovery of Anti-Glycation and AGEs breaker Agents and Study of their Mechanism of Action
  187. Jakyakgamcho-tang and its major component, Paeonia lactiflora, exhibit potent anti-glycation properties
  188. Clinical trials update from the European Society of Cardiology Heart Failure Meeting 2010: TRIDENT 1, BENEFICIAL, CUPID, RFA‐HF, MUSIC, DUEL, handheld BNP …
  189. Alteration of pressure-induced vasodilation in aging and diabetes, a neuro-vascular damage
  190. Targeting matrix remodeling in cardiac hypertrophy and heart failure
  191. The role of advanced glycation end products in retinal ageing and disease
  192. Targeting AGEs signaling ameliorates central nervous system diabetic complications in rats
  193. Arterial stiffness increases with deteriorating glucose tolerance status: the Hoorn Study
  194. Neurodegenerative diseases of the retina and potential for protection and recovery
  195. New drugs, procedures, and devices for hypertension
  196. Location of arterial stiffening differs in those with impaired fasting glucose versus diabetes: implications for left ventricular hypertrophy from the Multi-Ethnic Study of …
  197. Mechanisms of arterial remodeling: lessons from genetic diseases
  198. The accumulation of the glycoxidation product Nε-carboxymethyllysine in Cardiac Tissues with age, diabetes mellitus and coronary heart disease
  199. The effects of antihypertensive drugs on arterial stiffness
  200. Diabetic neuropathy is closely associated with arterial stiffening and thickness in type 2 diabetes
  201. Targeted reduction of advanced glycation improves renal function in obesity
  202. To AGE or not to age. The effect of physical activity and advanced glycation end-products (AGEs) on the vasculature in older individuals
  203. Characteristics, formation, and pathophysiology of glucosepane: a major protein cross-link
  204. Advanced glycation end‐products induce skeletal muscle atrophy and dysfunction in diabetic mice via a RAGE‐mediated, AMPK‐down‐regulated, Akt pathway
  205. Molecular mechanisms of diabetic cardiomyopathy
  206. Glycation: Implication in perceived age and dermatology
  207. Type-I Angiotensin II Receptor Blockade Reduces Uremia-induced Deterioration of Bone Material
  208. (−)-Epicatechin Ameliorates Cardiac Fibrosis in a Female Rat Model of Pre-Heart Failure with Preserved Ejection Fraction
  209. Advanced glycation and advanced lipoxidation: possible role in initiation and progression of diabetic retinopathy
  210. Protective effect of vanillin on diabetic nephropathy by decreasing advanced glycation end products in rats
  211. Compounds that combine aldose reductase inhibitory activity and ability to prevent the glycation (glucation and/or fructation) of proteins as putative …
  212. Alagebrium chloride, a novel AGE cross linkage breaker, inhibits neointimal proliferation after carotid balloon injury in diabetic animal model
  213. Cardiovascular prevention: relationships between arterial aging and chronic drug treatment
  214. Therapeutic options to reduce advanced glycation end products in patients with diabetes mellitus: A review
  215. Pathophysiology of diabetic retinopathy
  216. Heart failure: novel therapeutic approaches
  217. Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms
  218. Diabetic cardiomyopathy: do women differ from men?
  219. Clinic and ambulatory blood pressure in relation to the interaction between plasma advanced glycation end products and sodium dietary intake and renal handling
  220. Response to “A Short Insight on Two Different Aspects of Arterial Stiffness”; Moving Forward or Backward?
  221. Renoprotective antioxidant effect of alagebrium in experimental diabetes
  222. Arterial stiffness and hand osteoarthritis: a novel relationship?
  223. Plasma advanced glycation end products (AGEs) and NF-κB activity are independent determinants of diastolic and pulse pressure
  224. Heart failure with normal ejection fraction
  225. Contractile dysfunction in hypertrophied hearts with deficient insulin receptor signaling: possible role of reduced capillary density
  226. The receptor for advanced glycation endproducts (RAGE) and cardiovascular disease
  227. Linking RAGE and Nox in diabetic micro-and macrovascular complications
  228. The next generation of diabetic nephropathy therapies: an update
  229. Epicatechin breaks preformed glycated serum albumin and reverses the retinal accumulation of advanced glycation end products
  230. RAGE and cardiovascular disease
  231. Vieillissement: rôle et contrôle de la glycation
  232. Therapeutic potential of α-crystallin
  233. The role of advanced glycation end products in the development of atherosclerosis
  234. Senescence mediated redox imbalance in cardiac tissue: Antioxidant rejuvenating potential of green tea extract
  235. Effects of body mass index, plasma glucose and cholesterol levels on isolated systolic hypertension
  236. Collagen crosslinking: effect on structure, mechanics and fibrosis progression
  237. Arterial stiffness and arterial wave reflections are associated with systolic and diastolic function in patients with normal ejection fraction
  238. Influence of lifestyle modification on arterial stiffness and wave reflections
  239. The kidney in diabetes: dynamic pathways of injury and repair. The Camillo Golgi Lecture 2007
  240. Aging and ocular tissue stiffness in glaucoma
  241. Emerging role of advanced glycation-end products (AGEs) in the pathobiology of eye diseases
  242. The role of advanced glycation end products on sarcoplasmic reticulum calcium handling during diabetic cardiomyopathy
  243. Tiny molecule, big power: multi-target approach for curcumin in diabetic cardiomyopathy
  244. Higher levels of advanced glycation endproducts in human carotid atherosclerotic plaques are associated with a rupture-prone phenotype
  245. Microvascular degenerative complications are associated with increased aortic stiffness in type 2 diabetic patients
  246. Arterial stiffness in renal patients: an update
  247. Structural proteins and arterial ageing
  248. The role of AGEs in cardiovascular disease
  249. Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular …
  250. Pharmacologic approaches against advanced glycation end products (AGEs) in diabetic cardiovascular disease
  251. Vascular compliance in hypertension: therapeutic implications
  252. Mechanistic targeting of advanced glycation end-products in age-related diseases
  253. Advanced glycation end products (AGEs), receptor for AGEs, diabetes, and bone: review of the literature
  254. Therapeutic interventions against accumulation of advanced glycation end products (AGEs)
  255. Diabetes mellitus worsens diastolic left ventricular dysfunction in aortic stenosis through altered myocardial structure and cardiomyocyte stiffness
  256. Renal accumulation and clearance of advanced glycation end-products in type 2 diabetic nephropathy: effect of angiotensin-converting enzyme and …
  257. Emerging drugs for acute and chronic heart failure: current and future developments
  258. Skin autofluorescence corresponds to microvascular reactivity in diabetes mellitus
  259. Mutational Studies of the Receptor for Advanced Glycation End Products (RAGE) Inhibition
  260. Pharmacological evaluation of novel alagebrium analogs as methylglyoxal scavengers in vitro in cardiac myocytes and in vivo in SD rats
  261. Effect of ageing on left ventricular compliance and distensibility in healthy sedentary humans
  262. Emerging concepts in cardiac matrix biology
  263. Model studies of advanced glycation end product modification of heterograft biomaterials: The effects of in vitro glucose, glyoxal, and serum albumin on collagen …
  264. Novel therapeutic targets for diabetic nephropathy
  265. Glycative stress and anti-aging: 14. Regulation of Glycative stress. 2. Inhibition of the AGE production and accumulation
  266. Cytotoxicity of advanced glycation endproducts in human micro-and astroglial cell lines depends on the degree of protein glycation
  267. Alagebrium (ALT-711) improves the anti-hypertensive efficacy of nifedipine in diabetic-hypertensive rats
  268. Large elastic artery stiffness with aging: novel translational mechanisms and interventions
  269. Research Article Targeting AGEs Signaling Ameliorates Central Nervous System Diabetic Complications in Rats
  270. A comparison of dicarbonyl stress and advanced glycation endproducts in lifelong endurance athletes vs. sedentary controls
  271. Advanced glycation end-products as a potential target for treatment of cardiovascular disease
  272. ASSOCIATION FOR ACADEMIC SURGERY AND SOCIETY OF UNIVERSITY SURGEONS—ABSTRACTS 260
  273. Cardiac fibrosis and aging
  274. Metabolic parameters associated with arterial stiffness in older adults with Type 2 diabetes: the Edinburgh Type 2 diabetes study
  275. Advanced glycation end products and cardiovascular disease
  276. In vitro and in vivo antiglycation effects of connarus ruber extract
  277. Arterial stiffness in predialysis patients with uremia
  278. ADVANCED GLYCATED END PRODUCTS: A REVIEW
  279. Longitudinal changes in vascular risk markers and mortality rates among a Latino population with hypertension
  280. The axis AGE-RAGE-soluble RAGE and oxidative stress in chronic kidney disease
  281. Molecular mechanisms associated with diabetic endothelial–erectile dysfunction
  282. Advanced glycation end product (AGE) accumulation in the skin is associated with depression: the Maastricht study
  283. Functional and Hemodynam ic Cardiac Determinants of Exercise Capacity in Patients with Systolic Heart Failure
  284. Advanced glycation end-products in cardiac and renal failure
  285. Arterial stiffness and stroke: de-stiffening strategy, a therapeutic target for stroke
  286. Agents in development for the treatment of diabetic nephropathy
  287. The AGE–RAGE pathway and its relation to cardiovascular disease in patients with chronic kidney disease
  288. Clinical applications of arterial stiffness: therapeutics and pharmacology
  289. Future treatment of hypertension: shifting the focus from blood pressure lowering to arterial stiffness modulation?
  290. Of mice and men: models and mechanisms of diabetic cardiomyopathy
  291. What are new avenues for renal protection, in addition to RAAS inhibition?
  292. Medical treatment of Marfan syndrome: a time for change
  293. Therapeutic modification of arterial stiffness: An update and comprehensive review
  294. The possible role of advanced glycation endproducts (AGEs) in experimentally-induced ischemic brain damage.
  295. Age-related intimal stiffening enhances endothelial permeability and leukocyte transmigration
  296. Slowing arterial aging: how far have we progressed?
  297. Obesity and vascular compliance
  298. Arterial stiffness, vascular calcification and bone metabolism in chronic kidney disease
  299. Skin autofluorescence is increased in systemic lupus erythematosus but is not reflected by elevated plasma levels of advanced glycation endproducts
  300. Intraoperative sRAGE-Kinetik: Ein neuer altersbezogener Outcome-Prädiktor der kardialen Chirurgie
  301. Alpha-dicarbonyl stress: implications for obesity and type 2 diabetes?
  302. Central arterial aging and the epidemic of systolic hypertension and atherosclerosis
  303. Advanced glycation end-products, measured as skin autofluorescence, associate with vascular stiffness in diabetic, pre-diabetic and normoglycemic …
  304. Ageing and vascular ageing
  305. Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes
  306. The bencfit-to-risk ratio of common treatments in PCOS: effect of oral contraceptives versus metformin on atherogenic markers
  307. Oxidative stress and diabetic retinopathy: Molecular mechanisms, pathogenetic role and therapeutic implications
  308. RAGE in the pathophysiology of skeletal muscle
  309. Differential effects of glyoxalase 1 overexpression on diabetic atherosclerosis and renal dysfunction in streptozotocin‐treated, apolipoprotein E‐deficient mice
  310. Corneal stiffness and collagen cross-linking proteins in glaucoma: Potential for novel therapeutic strategy
  311. Why don’t fistulas mature?
  312. New insights into the causes of heart failure
  313. Receptor for advanced glycation endproducts and atherosclerosis: from basic mechanisms to clinical implications
  314. 5. Crucial involvement of advanced glycation end-products in experimental diabetes-associated arterial elastocalcinosis.
  315. The future of aging therapies
  316. Soluble receptor for advanced glycation end products and increased aortic stiffness in the general population
  317. Influence of RAGE Signaling on Cellular Communication in Diabetes-Mediated Vascular Calcification
  318. Current concepts in the management of diabetic nephropathy
  319. Prognostic impact of aortic stiffness in high-risk type 2 diabetic patients: the Rio de Janeiro Type 2 Diabetes Cohort Study
  320. Role of advanced glycation end products in cardiovascular disease
  321. Diabetic Kidney Disease: From Pathogenesis to Novel Treatment Possibilities
  322. The metabolic syndrome in elderly individuals is associated with greater muscular, but not elastic arterial stiffness, independent of low-grade inflammation, endothelial …
  323. Lifelong cyclic mechanical strain promotes large elastic artery stiffening: increased pulse pressure and old age-related organ failure
  324. Arterial blood pressure and stiffness in hypertension: is arterial structure important?
  325. Erectile dysfunction in the elderly: epidemiology, etiology and approaches to treatment
  326. Physical activity and markers of glycation in older individuals: data from a combined cross-sectional and randomized controlled trial (EXAMIN age)
  327. Challenging but essential targets for genuine anti-ageing drugs
  328. Ventricular arterial stiffening: integrating the pathophysiology
  329. Diabetic cardiomyopathy: signaling defects and therapeutic approaches
  330. Inhibition of NA+/H+ Exchanger 1 Attenuates Renal Dysfunction Induced by Advanced Glycation End Products in Rats
  331. Blood pressure, large arteries and atherosclerosis
  332. Elevated serum advanced glycation end products and their circulating receptors are associated with anaemia in older community-dwelling women
  333. Conundrum of pathogenesis of diabetic cardiomyopathy: role of vascular endothelial dysfunction, reactive oxygen species, and mitochondria
  334. Vascular Stiffness
  335. Induction and rescue of skeletal fragility in a high-fat diet mouse model of type 2 diabetes: An in vivo and in vitro approach
  336. Nutrition, Diet, and Supplements for Peak Physical & Mental Performance
  337. Measurement of arterial stiffness: a novel tool of risk stratification in hypertension
  338. Receptor for Advanced Glycation End Product, Organ Crosstalk, and Pathomechanism Targets for Comprehensive Molecular Therapeutics in Diabetic Ischemic Stroke
  339. Alagebrium and spironolactone ameliorate dietary induced metabolic syndrome in male Wister rats
  340. Advanced glycation endproducts: a biomarker for age as an outcome predictor after cardiac surgery?
  341. Lens aging: effects of crystallins
  342. Secondary metabolites from lichen as potent inhibitors of advanced glycation end products and vasodilative agents
  343. Point of NO return for nitrergic nerves in diabetes: a new insight into diabetic complications
  344. Diabetic hyperglycemia promotes primary tumor progression through glycation-induced tumor extracellular matrix stiffening
  345. The Role of Cortical and Cancellous Bone Quality on Vertebral Fragility
  346. Alagebrium and Spironolactone Ameliorate Dietary Induced Metabolic Syndrome in Male Wister Rats
  347. Aging and glycoxidant stress
  348. Microvascular and lymphatic dysfunction in HFpEF and its associated comorbidities
  349. Advanced glycation end products and vascular structure and function
  350. Nondiabetic glucometabolic status and progression of aortic stiffness: the Whitehall II Study
  351. Uncertainty quantification and sensitivity analysis of an arterial wall mechanics model for evaluation of vascular drug therapies
  352. Extracellular Matrix Viscoelasticity Drives Liver Cancer Progression in Pre-Cirrhotic NASH
  353. Below the Radar: Advanced Glycation End Products that Detour “around the side”: Is HbA1c not an accurate enough predictor of long term progression and …
  354. Accumulation of advanced glycation end products and chronic complications in ESRD treated by dialysis
  355. Drug discovery for heart failure: a new era or the end of the pipeline?
  356. Alterations in myofilament calcium sensitivity and calcium regulation in type 2 diabetic rat heart
  357. Using myocardial imaging to identify and manage subclinical heart disease in diabetes mellitus and obesity
  358. Future Therapies in Diastolic Heart Failure
  359. Avenues for post-translational protein modification prevention and therapy
  360. Chemical Approaches to Modulate Biological Processes: Unique Activity of N-Phenacylthiazolium Compounds, Bacterial Cell Wall Engineering and Other …
  361. Therapeutic agents targeting at AGE-RAGE axis for the treatment of diabetes and cardiovascular disease: a review of clinical evidence
  362. Zagazig University Medical Journa l
  363. Different impact of hemodialysis vintage on cause-specific mortality in long-term hemodialysis patients
  364. Advanced glycation end products: sparking the development of diabetic vascular injury
  365. Deterioration of Glutaraldehyde crosslinked Heterograft Biomaterials due to Advanced Glycation End Product Formation and Serum Albumin Infiltration
  366. Advanced glycation end-product peptides are associated with impaired renal function, but not with biochemical markers of endothelial dysfunction and inflammation …
  367. Relation of aortic distensibility determined by magnetic resonance imaging in patients≥ 60 years of age to systolic heart failure and exercise capacity
  368. Arterial compliance in the elderly: its effect on blood pressure measurement and cardiovascular outcomes
  369. Cardiac Fibrosis and Aging
  370. Large arteries and the kidney
  371. Hypertension, diabetes type II, and their association: role of arterial stiffness
  372. Obesity in a model of gpx4 haploinsufficiency uncovers a causal role for lipid-derived aldehydes in human metabolic disease and cardiomyopathy
  373. The diabetic cardiomyopathy: the contributing pathophysiological mechanisms
  374. Methylglyoxal-induced increase in peroxynitrite and inflammation related to diabetes
  375. Annual update 2004/2005-Treatment of cardiovascular disorders
  376. Extracellular matrix changes and vascular smooth muscle signaling
  377. Mechanical factors in arterial aging: a clinical perspective
  378. Novel therapies for diabetic kidney disease
  379. Advanced glycation end-products: implications for diabetic and non-diabetic nephropathies
  380. Novel therapeutic strategies for reducing arterial stiffness
  381. Heart failure with preserved ejection fraction: an ongoing enigma
  382. AGE–RAGE stress, stressors, and antistressors in health and disease
  383. 5 Diabetes and Advanced
  384. Decreasing arterial aging by controlling blood pressure levels and hypertension: a step forward
  385. Pacing and Diastolic Heart Failure
  386. Role of advanced glycation end products (AGEs) and its receptor (RAGE)-mediated diabetic vascular complications
  387. Free radicals in aging: causal complexity and its biomedical implications
  388. Cardiovascular Complications in Renal Failure: Implications of Advanced Glycation End Products and Their Receptor RAGE
  389. RAGE signaling in inflammation and arterial aging
  390. Effect of Nebivolol and Lifestyle Modification on Large Artery Stiffness in Middle-Aged and Older Hypertensive Adults
  391. Receptor for advanced glycation end products and the cardiovascular complications of diabetes and beyond: lessons from AGEing
  392. Vascular Stiffening Regulates Endothelial Permeability And Smooth Muscle Cell Motility
  393. Prevention and reversal of diabetic nephropathy in db/db mice treated with alagebrium (ALT-711)
  394. Advanced glycation end product associated skin autofluorescence: a mirror of vascular function?
  395. SENS Foundation: Accelerating Progress Toward Biomedical Rejuvenation
  396. Benefit of glyceryl trinitrate on arterial stiffness is directly due to effects on peripheral arteries
  397. The AGE-RAGE axis: implications for age-associated arterial diseases
  398. Combined immunoelectron microscopic and computer-assisted image analyses to detect advanced glycation end-products in human myocardium
  399. How to treat arterial stiffness beyond blood pressure lowering?
  400. Pregnancy and Hypertension
  401. Diabetes and advanced glycoxidation end products
  402. Central blood pressure and hypertension: role in cardiovascular risk assessment
  403. Emerging drugs for diabetic nephropathy
  404. Mechanisms of vascular aging: new perspectives
  405. Vascular Endothelial Growth Factor as a Determinant of Diabetic Nephropathy
  406. Early-and advanced non-enzymatic glycation in diabetic vascular complications: the search for therapeutics
  407. Journal of Pharmaceutical and Scientific Innovation
  408. Sodium nitrite de-stiffening of large elastic arteries with aging: role of normalization of advanced glycation end-products
  409. Relationship of advanced glycation end products with cardiovascular disease in menopausal women
  410. Carotid artery stiffness and diastolic function in subjects without known cardiovascular disease
  411. Association between systemic arterial stiffness and age-related macular degeneration
  412. Age-related vascular stiffening: causes and consequences
  413. Nitrite-induced cross-linking alters remodeling and mechanical properties of collagenous engineered tissues
  414. Glycation, carbonyl stress and AGEs inhibitors: a patent review
  415. Novel therapies in acute and chronic heart failure
  416. Decreasing Arterial Stiffness and/or Wave Reflections Independently of Mean Arterial Pressure: Effect of Non-antihypertensive Drugs (Part 2)
  417. Serum carboxymethyl-lysine, a dominant advanced glycation end product, is associated with chronic kidney disease: the Baltimore longitudinal study of aging
  418. Lens fluorescence and accommodative amplitude in pre-presbyopic and presbyopic subjects
  419. Arterial Stiffness and Hypertension–Which Comes First?
  420. Coronary microvascular disease as an early culprit in the pathophysiology of diabetes and metabolic syndrome
  421. Foreseeable and more distant rejuvenation therapies
  422. Role of oxidative stress and targeted antioxidant therapies in experimental models of diabetic complications
  423. Reduction of advanced-glycation end products levels and inhibition of RAGE signaling decreases rat vascular calcification induced by diabetes
  424. Alagebrium Mitigates Metabolic Insults in High Carbohydrate and High Fat Diet Fed Wistar Rats
  425. Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension
  426. Is human aging still mysterious enough to be left only to scientists?
  427. Peel extract of water chestnut (Trapa bispinosa Roxb.) inhibits glycation, degradesα-dicarbonyl compound, and breaks advanced glycation end product …
  428. Heart failure with normal left ventricular ejection fraction: what is the evidence?
  429. Arterial stiffness as a measure of vascular dysfunction in hypertensive women
  430. Pharmacological modulation of arterial stiffness
  431. Elevated pulse pressure, intraoperative hemodynamic perturbations, and acute kidney injury after coronary artery bypass grafting surgery
  432. Is increased arterial stiffness a cause or consequence of atherosclerosis?
  433. A strategy for postponing aging indefinitely
  434. Alagebrium inhibits neointimal hyperplasia and restores distributions of wall shear stress by reducing downstream vascular resistance in obese and diabetic rats
  435. Correlates of aortic stiffness progression in patients with type 2 diabetes: importance of glycemic control: the Rio de Janeiro type 2 diabetes cohort study
  436. Heart failure in type 2 diabetes mellitus: impact of glucose-lowering agents, heart failure therapies, and novel therapeutic strategies
  437. Implication of advanced glycation end products (Ages) and their receptor (Rage) on myocardial contractile and mitochondrial functions
  438. Valsartan improves arterial stiffness in type 2 diabetes independently of blood pressure lowering
  439. Cardiovascular effects of 1 year of alagebrium and endurance exercise training in healthy older individuals
  440. The RAGE axis and endothelial dysfunction: maladaptive roles in the diabetic vasculature and beyond
  441. Metabolic syndrome amplifies the age-associated increases in vascular thickness and stiffness
  442. Pathophysiology and medical treatment of carotid artery stenosis
  443. Reversing chronic remodeling in heart failure
  444. Role of arterial stiffness in cardiovascular disease
  445. Free radicals in aging: causal complexity and its biomedical implications
  446. 7Uncertainty quantification and
  447. Advanced glycation: how are we progressing to combat this web of sugar anomalies in diabetic nephropathy
  448. Pharmacologic approaches to reduce arterial stiffness
  449. Using Diet-induced Obesity to Examine the Role for Advanced Glycation End-products in Metabolic Osteoarthritis Pathogenesis in Young Rats
  450. Advanced glycation end-products induce basement membrane hypertrophy in endoneurial microvessels and disrupt the blood–nerve barrier by stimulating …
  451. A Study to Evaluate the Associated Systemic Risk Factors in Type 2 Diabetes Mellitus patients with Clinically Significant Macular Edema
  452. The role of fibrinogen glycation in ATTR: evidence for chaperone activity loss in disease
  453. Advanced glycation end products: role in pathology of diabetic cardiomyopathy
  454. Targeting Blood Pressure Lowering and the Sympathetic Nervous System
  455. Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials
  456. Advanced glycation end products and the kidney
  457. Sex-specific association of age with carotid artery distensibility: multi-ethnic study of atherosclerosis
  458. Aortic stiffness in aging and hypertension: prevention and treatment with habitual aerobic exercise
  459. Age associated changes of AGE-receptor expression: RAGE upregulation is associated with human heart dysfunction
  460. Role of Amino Acids on Prevention of Nonenzymatic Glycation of Lens Proteins in Senile and Diabetic Cataract
  461. The glycation pathway in type 2 diabetes and cardiovascular disease
  462. Arterial stiffness, its assessment, prognostic value, and implications for treatment
  463. The Role of Advanced Glycation in Diabetic Retinopathy
  464. Advanced glycation end products (AGEs) in diabetes
  465. Soluble receptor for advanced glycation end-products independently influences individual age-dependent increase of arterial stiffness
  466. Endocrine and molecular influences on testicular development in Meishan and White Composite boars
  467. Regional arterial stiffness in patients with type 2 diabetes and chronic kidney disease
  468. Research for Vascular Failure: Current Topics in China
  469. Myocardial infarction, heart failure and sympathetic nervous system activity: new pharmacological approaches that affect neurohumoral activation
  470. Discussion and future perspectives
  471. Advanced glycation end products and their circulating receptors predict cardiovascular disease mortality in older community-dwelling women
  472. Pulse pressure and adverse outcomes in women: a report from the Women’s Ischemia Syndrome Evaluation (WISE)
  473. Cardiac overexpression of antioxidant catalase attenuates aging-induced cardiomyocyte relaxation dysfunction
  474. New Approach to Preventing and Treating Diabetes Mellitus: Focus on Advanced Glycation End Products (AGE)
  475. Skin autofluorescence in diabetes mellitus
  476. Basic Science for Clinicians
  477. Current perspectives on the health risks associated with the consumption of advanced glycation end products: recommendations for dietary management
  478. Skin autofluorescence and pentosidine are associated with aortic stiffening: The Maastricht Study
  479. The Evolving Face of Heart Failure Associated with Elevated Cardio-Metabolic Risk Factors
  480. Dietary advanced glycation end-products: molecular mechanisms and preventive tools
  481. Pyridoxamine prevents age-related aortic stiffening and vascular resistance in association with reduced collagen glycation
  482. Aldosterone receptor inhibition alters the viscoelastic biomechanical behavior of the aortic wall
  483. Arterial remodeling and hypertensive damage: Clinical studies in patients with essential hypertension
  484. High serum levels of advanced glycation end products predict increased coronary heart disease mortality in nondiabetic women but not in nondiabetic men: a …
  485. Reduction of renal tubular injury with a RAGE inhibitor FPS-ZM1, valsartan and their combination in streptozotocin-induced diabetes in the rat
  486. Antihypertensive treatment alters the predictive strength of pulse pressure and other blood pressure measures
  487. Effects of supervised exercise and dietary nitrate in older adults with controlled hypertension and/or heart failure with preserved ejection fraction
  488. Medical treatment of diabetic retinopathy
  489. Cardiac-specific overexpression of insulin-like growth factor 1 attenuates aging-associated cardiac diastolic contractile dysfunction and protein damage
  490. Advanced glycation endproduct-induced diabetic complications
  491. Stimulatory effects of non-enzymatic glycation on fibronectin matrix assembly
  492. Protein glycation: a firm link to endothelial cell dysfunction
  493. Diabetic cardiomyopathy: A new perspective of mechanistic approach
  494. Advanced glycation end products are associated with inflammation and endothelial dysfunction in HIV
  495. The development of maillard reaction, and advanced glycation end product (AGE)-receptor for AGE (RAGE) signaling inhibitors as novel therapeutic strategies for …
  496. Advanced glycation end products and diabetic cardiovascular disease
  497. A novel improved therapy strategy for diabetic nephropathy: targeting AGEs
  498. Molecular effects of advanced glycation end products on cell signalling pathways, ageing and pathophysiology
  499. The glymphatic system and waste clearance with brain aging: a review
  500. Role of methylglyoxal in the pathogenesis of insulin resistance
  501. Pre-Diabetes, Cardiovascular Risk Factors, Arterial Stiffness—ADMA: Mechanisms of Pre-Diabetes and Diabetes: Modulation of Cardiac Tissues
  502. Renal nerve ablation reduces augmentation index in patients with resistant hypertension
  503. Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications
  504. Advanced glycation end products and risks for chronic diseases: intervening through lifestyle modification
  505. Regional arterial stiffness associated with ischemic heart disease in type 2 diabetes mellitus
  506. Prevention of vascular complications in diabetes mellitus patients: focus on the arterial wall
  507. Vascular aging: a tale of EVA and ADAM in cardiovascular risk assessment and prevention
  508. Novel drug treatment for diabetic nephropathy
  509. Treatment and control of high blood pressure in adults
  510. Advanced glycation endproducts regulate smooth muscle cells calcification in cultured HSMCs
  511. Molecular mechanisms of vascular dysfunction and cardiovascular biomarkers in type 2 diabetes
  512. Aging hearts and vessels: masters of adaptation and survival
  513. Limited joint mobility (LJM) in elderly subjects with type II diabetes mellitus
  514. Proinflammation of aging central arteries: a mini-review
  515. Clinical potential of advanced glycation end-product inhibitors in diabetes mellitus
  516. Reduced wall compliance suppresses Akt-dependent apoptosis protection stimulated by pulse perfusion
  517. Modulation of advanced glycation endproducts (AGEs) signaling in experimentally induced stroke in mice.
  518. Curcumin ameliorates arterial dysfunction and oxidative stress with aging
  519. Arginase inhibition restores NOS coupling and reverses endothelial dysfunction and vascular stiffness in old rats
  520. Characterizing the advanced glycation endproducts formation of proteins and nucleotides by methylglyoxal and glyoxal
  521. Structural alterations in arterial stiffness: role of arterial fibrosis
  522. Structural and functional properties, chaperone activity and posttranslational modifications of alpha-crystallin and its related subunits in the crystalline lens: N …
  523. Arterial Destiffening With Weight Loss in Overweight and Obese Middle-Aged and Older Adults
  524. Arterial stiffness in the heart disease of CKD
  525. Uremic toxicity of advanced glycation end products in CKD
  526. Peel extract of water chestnut (Trapa bispinosa Roxb.) inhibits glycation, degradesα-dicarbonyl compound, and breaks advanced glycation end product crosslinks
  527. Exercise, advanced glycation end products, and their effects on cardiovascular disorders: A narrative review
  528. Advanced glycation end products upregulate lysyl oxidase and endothelin-1 in human aortic endothelial cells via parallel activation of ERK1/2–NF-κB and JNK–AP-1 …
  529. Study of advanced glycation endproducts (AGEs) of human fibrinogen and nucleobases with methyl glyoxal: An in vitro investigation of ages formation
  530. Pharmacological and non-pharmacological treatment of endothelial dysfunction: relevance to diabetes
  531. AGE/non-AGE glycation: An important event in rheumatoid arthritis pathophysiology
  532. RAGE: a multi-ligand receptor unveiling novel insights in health and disease
  533. Matrix metalloproteinase 2 activation of transforming growth factor-β1 (TGF-β1) and TGF-β1–type II receptor signaling within the aged arterial wall
  534. Advanced glycation end-products (AGEs) and their soluble receptor (sRAGE) in women suffering from systemic lupus erythematosus (SLE)
  535. Vascular changes in type 2 diabetes mellitus: Application to restenosis after stenting
  536. Apparent treatment-resistant hypertension and chronic kidney disease: another cardiovascular-renal syndrome?
  537. Glycation and Glycosylation in Cardiovascular Remodeling: Focus on Advanced Glycation End Products and O-Linked Glycosylations as Glucose-Related …
  538. Do advanced glycation end products and its receptor play a role in pathophysiology of hypertension?
  539. Advanced glycation end products (AGEs) and its receptor, RAGE, modulate age-dependent COVID-19 morbidity and mortality. A review and hypothesis
  540. Preservation of pressure-induced cutaneous vasodilation by limiting oxidative stress in short-term diabetic mice
  541. AGE-RAGE Axis in the Aging and Diabetic Heart
  542. Quantitative analysis of the effect of diabetes on fibroflast migration
  543. The roles of protein glycation, glycoxidation, and advanced glycation end-product formation in diabetes-induced atherosclerosis
  544. Uremic toxin–targeting as a therapeutic strategy for preventing cardiorenal syndrome
  545. Diastolic dysfunction of aging is independent of myocardial structure but associated with plasma advanced glycation end-product levels
  546. Evolution and modulation of age-related medial elastocalcinosis: impact on large artery stiffness and isolated systolic hypertension
  547. Contribution of receptor for advanced glycation end products to vasculature-protecting effects of exercise training in aged rats
  548. Endurance exercise training attenuates fibrosis and collagen cross-linking in myocardium of aged rats
  549. Effects of hot water extract of mangosteen pericarp on vascular function: Re-analysis focusing on factors affecting vascular function
  550. Aortic stiffness: epidemiology, risk factors, and relevant biomarkers
  551. The evolution of systolic blood pressure as a strong predictor of cardiovascular risk and the effectiveness of fixed-dose ARB/CCB combinations in lowering levels of …
  552. Diabetes with heart failure increases methylglyoxal modifications in the sarcomere, which inhibit function
  553. Arterial stiffness: a potential therapeutic target to reduce cardiovascular mortality
  554. PRECLINICAL STUDIES ON PTEROSTILBENE FOR DIABETIC CARDIOMYOPATHY
  555. The role of collagen crosslinks on passive cardiac mechanics in volume-overload hypertrophy
  556. Mechanisms, pathophysiology, and therapy of arterial stiffness
  557. Pyridoxamine ameliorates the effects of advanced glycation end products on subtotal nephrectomy induced chronic renal failure rats
  558. Protein glycation and oxidative stress in pathophysiology of diabetic complications
  559. Diastolic dysfunction in hypertension
  560. Arterial stiffness and cardiovascular therapy
  561. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part I: aging arteries: a “set up” for vascular disease
  562. Aminoguanidine prevents fructose-induced arterial stiffening in Wistar rats: aortic impedance analysis
  563. Arterial aging: is it an immutable cardiovascular risk factor?
  564. Ischemia-modified albumin is associated with arterial stiffness in hemodialysis patients
  565. Can targeting the incretin pathway dampen RAGE-mediated events in diabetic nephropathy?
  566. Aging and arterial stiffness
  567. The central arterial burden of the metabolic syndrome is similar in men and women: the SardiNIA Study
  568. Heart failure with preserved ejection fraction: is there a passage between Scylla and Charybdis?
  569. Chronic kidney disease as a risk factor for heart failure with preserved ejection fraction: a focus on microcirculatory factors and therapeutic targets
  570. Substrate stiffness regulates PDGF-induced circular dorsal ruffle formation through MLCK
  571. Identification and characterization of enzymes responsible for methylglyoxal overproduction in the metabolic syndrome
  572. High-molecular-weight advanced glycation end products disturb the vasomotor balance in rat aortic rings through superoxide formation
  573. Advanced glycation end products: potential mechanism and therapeutic target in cardiovascular complications under diabetes
  574. Prognostic impact of changes in aortic stiffness for cardiovascular and mortality outcomes in individuals with type 2 diabetes: the Rio de Janeiro cohort study
  575. Arterial destiffening with atorvastatin in overweight and obese middle-aged and older adults
  576. The role of titin and extracellular matrix remodelling in heart failure with preserved ejection fraction
  577. The importance of mechanical forces for in vitro endothelial cell biology
  578. The role of advanced glycation end-products in the development of coronary artery disease in patients with and without diabetes mellitus: a review
  579. Brachial pressure–independent reduction in carotid stiffness after long-term angiotensin-converting enzyme inhibition in diabetic hypertensives
  580. Influence of regular exercise on age-related changes in arterial elasticity: mechanistic insights from wall compositions in rat aorta
  581. Targeting the arterial wall, but what is the target?
  582. Age-related changes in the mechanical properties of large arteries
  583. Localised micro-mechanical stiffening in the ageing aorta
  584. Advanced glycation end products: A potential contributor of oxidative stress for cardio-vascular problems in diabetes
  585. Heart failure with normal ejection fraction
  586. Advanced glycation end products and oxidative stress in a hyperglycaemic environment
  587. New therapeutic agents for diabetic kidney disease
  588. 9 Cardiovascular Changes with Aging
  589. Methylglyoxal, oxidative stress, and aging
  590. Role of advanced glycation end products in carcinogenesis and their therapeutic implications
  591. Central arterial aging: humans to molecules
  592. Multiphoton imaging of induced autofluorescent advanced glycation end products in porcine aorta
  593. AGEs induce ectopic endochondral ossification in intervertebral discs
  594. Heart, aging, and hypertension
  595. Receptor for AGE (RAGE) mediates neointimal formation in response to arterial injury
  596. Advanced glycation end products present in the obese uterine environment compromise preimplantation embryo development
  597. Multiphoton imaging of autofluorescent advanced glycation end product formation in porcine aorta
  598. Arterial stiffness as a cause of resistant hypertension?
  599. Dietary glycotoxins and infant formulas
  600. Diabetic patients and kidney protection: an attainable target
  601. Advanced glycation end products in diabetic retinopathy and phytochemical therapy
  602. A meta-analysis of the mechanism of blood pressure change with aging
  603. Pioglitazone improves aortic wall elasticity in a rat model of elastocalcinotic arteriosclerosis
  604. Wall stiffness suppresses Akt/eNOS and cytoprotection in pulse-perfused endothelium
  605. Ascorbic acid selectively improves large elastic artery compliance in postmenopausal women
  606. Bibliography Current World Literature Vol 23 No 4 July 2008
  607. Role of titin and collagen in the diastolic dysfunction of cirrhotic cardiomyopathy
  608. Glycoxidative stress and cardiovascular complications in experimentally-induced diabetes: effects of antioxidant treatment
  609. Matrix metalloproteinase-3 genotype contributes to age-related aortic stiffening through modulation of gene and protein expression
  610. Arterial stiffness in chronic inflammatory diseases
  611. Aortic stiffness is reduced beyond blood pressure lowering by short-term and long-term antihypertensive treatment: a meta-analysis of individual data in 294 patients
  612. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are correlated with AGEs in both diabetic and non-diabetic subjects
  613. Arterioventricular coupling and ventricular efficiency after antihypertensive therapy: a noninvasive prospective study
  614. Skin autofluorescence relates to soluble receptor for advanced glycation end-products and albuminuria in diabetes mellitus
  615. A hypothesis: moderate consumption of alcohol contributes to lower prevalence of type 2 diabetes due to the scavenging of alpha-dicarbonyls by dietary polyphenols
  616. The reality of aging viewed from the arterial wall
  617. Aortic Stiffness: Review of Life Course, Epidemiology, Risk Factors, and Relevant Biomarkers
  618. Cardiovascular Changes with Aging
  619. 24 Carotid intima–media thickness and arterial stiffness: indicators of cardiovascular risk and modifications by treatment
  620. Cardiac Specific Overexpression of Insulin-Like Growth Factor-1 (IGF-1) Attenuates Aging-Associated Cardiac Diastolic Contractile Dysfunction and Protein Damage
  621. Sex differences in age-related stiffening of the aorta in subjects with type 2 diabetes
  622. Basic and clinical research against advanced glycation end products (AGEs): new compounds to tackle cardiovascular disease and diabetic complications
  623. Stiffness-induced endothelial DLC-1 expression forces leukocyte spreading through stabilization of the ICAM-1 adhesome
  624. New antihypertensive drugs under development
  625. Effect of Citrullus colocynthis extract on glycated hemoglobin formation (in vitro)
  626. MRI and Echo Assessment of the Diastolic Dysfunction of Normal Aging: Altered LV Pressure Decline or Load?
  627. Aldose reductase regulates hyperglycemia-induced HUVEC death via SIRT1/AMPK-α1/mTOR pathway
  628. Endothelial dysfunction in diabetes: from mechanisms to therapeutic targets
  629. CHRONIC LOW INTENSITY CONTINUOUS AND INTERVAL TRAINING PREVENT HEART FAILURE-RELATED CORONARY ARTERY STIFFNESS
  630. Dynamic changes in myocardial matrix and relevance to disease: translational perspectives
  631. Functional aortic stiffness: role of CD4+ T lymphocytes
  632. Assessment of vascular wall shear stress and implications for atherosclerotic disease
  633. VU Research Portal
  634. Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve …
  635. Causes and consequences of increased arterial stiffness in chronic kidney disease patients
  636. Role of antihypertensive drugs in arterial ‘de-stiffening’and central pulsatile hemodynamics
  637. Identifying and interpreting novel targets that address more than one diabetic complication: a strategy for optimal end organ protection in diabetes
  638. Review paper Arterial stiffness as a new marker for cardiovascular disease
  639. Arterial stiffness and hypertension: emerging concepts
  640. Ultrasonic delineation of aortic microstructure: the relative contribution of elastin and collagen to aortic elasticity
  641. The metabolic syndrome, cardiopulmonary fitness, and subcutaneous trunk fat as independent determinants of arterial stiffness: the Amsterdam Growth and Health …
  642. Nitric oxide and the regulation of large artery stiffness: from physiology to pharmacology
  643. Strategies for achieving healthy vascular aging
  644. The role of titin and extracellular matrix remodelling in HFpEF
  645. Pathogenesis of elevated peripheral pulse pressure: some reflections and thinking forward
  646. Nuclear Expression and DNA Binding Capacity of Receptor for Advanced Glycation End Products in Renal Tissue
  647. Aging and arterial structure-function relations
  648. Determinants of progression of aortic stiffness in hemodialysis patients: a prospective longitudinal study
  649. Arterial compliance of rowers: implications for combined aerobic and strength training on arterial elasticity
  650. Relation of diabetes to coronary artery ectasia: A meta-analysis study.
  651. Perivascular adipose tissue-mediated arterial stiffening in aging and disease: An emerging translational therapeutic target?
  652. Glycoxidation and diabetic complications: modern lessons and a warning?
  653. Structural remodeling in the limb circulation: impact of obesity and diabetes
  654. Mechanistic insight of diabetic nephropathy and its pharmacotherapeutic targets: an update
  655. Trends in advanced glycation end products research in diabetes mellitus and its complications
  656. Effects of low‐level light therapy on hepatic antioxidant defense in acute and chronic diabetic rats
  657. Clinical studies on coronary revascularization in patients with type 2 diabetes
  658. Regenerative therapies for diabetic microangiopathy
  659. Obesity, arterial stiffness, and cardiovascular risk
  660. Glyoxalase 1 modulation in obesity and diabetes
  661. Increased central arterial stiffness after spinal cord injury: contributing factors, implications, and possible interventions
  662. Central and peripheral blood pressures in relation to plasma advanced glycation end products in a Chinese population
  663. Prevention of protein glycation by nanoparticles: potential applications in T2DM and associated neurodegenerative diseases
  664. Cardiovascular disease: what’s all the AGE/RAGE about?
  665. Advanced Glycation End Products And Risks For Chronic Diseases: Intervening Through Lifestyle Modification
  666. Unfavorable effects of resistance training on central arterial compliance: a randomized intervention study
  667. High blood pressure and pulse pressure
  668. Arterial stiffness and cardiovascular risk in hypertension
  669. Advanced glycation end products and diabetic complications
  670. Aortic input impedance increases with age in healthy men and women
  671. Interaction between pulse wave velocity, augmentation index, pulse pressure and left ventricular function in chronic heart failure
  672. AGE-RAGE Axis in the Aging and Diabetic Heart: Prime Target for Adjunctive Therapeutic Intervention
  673. The age-related macular degeneration as a vascular disease: Contributions to the non-pharmacological interventions and pharmacological therapy arising from …
  674. Treatment of arterial remodeling in essential hypertension
  675. Linking diabetes and atherosclerosis
  676. Age-related changes in venticular–arterial coupling: pathophysiologic implications
  677. Arterial stiffness gradient
  678. A population-based assessment of 24-hour ocular perfusion pressure among patients with primary open angle glaucoma: the Handan Eye Study
  679. Association of 276G> T adiponectin gene polymorphism to plasma adiponectin and albuminuria in type 2 diabetic patients
  680. Glucose and blood pressure-dependent pathways–the progression of diabetic kidney disease
  681. Characteristics of rabbit ClC-2 current expressed in Xenopus oocytes and its contribution to volume regulation
  682. Glycated collagen I induces premature senescence-like phenotypic changes in endothelial cells
  683. Hypertension induces brain β-amyloid accumulation, cognitive impairment, and memory deterioration through activation of receptor for advanced glycation end …
  684. Aspects of hyperglycemia contribution to arterial stiffness and cardiovascular complications in patients with type 1 diabetes
  685. Pulse pressure and coronary atherosclerosis progression in postmenopausal women
  686. Angiotensin II contributes to arterial compliance in congestive heart failure
  687. Therapeutic potential of vitamin D in AGE/RAGE-related cardiovascular diseases
  688. The role of fibrinogen glycation in ATTR: evidence for chaperone activity loss in
  689. Drugs and the peroxisome proliferator activated receptors
  690. Endothelial dysfunction and arterial stiffness in coronary artery disease
  691. Will new antihypertensive drugs emerge? Part 1
  692. Arterial elasticity in cardiovascular disease: focus on hypertension, metabolic syndrome and diabetes
  693. In vitro system to study realistic pulsatile flow and stretch signaling in cultured vascular cells
  694. Mesenchymal stem cells: a future experimental exploration for recession of diabetic nephropathy
  695. Halting arterial aging in patients with cardiovascular disease: hypolipidemic and antihypertensive therapy
  696. Oxidative Stress in Retinal Diseases
  697. Similarities and differences between the pathogenesis and pathophysiology of diastolic and systolic heart failure
  698. Vascular stiffness and increased pulse pressure in the aging cardiovascular system
  699. Left Ventricular Diastolic Dysfunction in Essential Hypertension,’Evaluation by Doppler Echocardiography’
  700. Aortic stiffness as a surrogate endpoint to micro-and macrovascular complications in patients with type 2 diabetes
  701. A comparative study on skin and plasma advanced glycation end products and their associations with arterial stiffness
  702. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation
  703. Current concepts in targeted therapies for the pathophysiology of diabetic microvascular complications
  704. Does vascular elasticity affect arteriovenous fistula maturation?
  705. Remodeling of heterogeneous extracellular matrices of the diabetic nerve: Models and experiments
  706. Leg flow-mediated arterial dilation in elderly patients with heart failure and normal left ventricular ejection fraction
  707. Ventriculovascular coupling in systolic and diastolic heart failure
  708. Clinical Implication of Vascular Calcification in Patients Undergoing Hemodialysis: The End or the Beginning of Disease
  709. Arginase inhibition alleviates hypertension associated with diabetes: effect on endothelial dependent relaxation and NO production
  710. Arterial de-stiffing Drugs: Which Promising Therapeutic Agent is Useful?
  711. Heart failure with preserved ejection fraction: the new devil in the pandemic
  712. Arterial stiffness and coronary ischemic disease
  713. Characterization of cardiac time intervals in healthy bonnet macaques (Macaca radiata) by using an electronic stethoscope
  714. Advanced glycation end products: new clinical and molecular perspectives
  715. A comparative study of levels of methylglyoxal and reduced glutathione in different organs of rats treated with high carbohydrate diets
  716. Increased arterial stiffness is independently related to cerebrovascular disease and aneurysms of the abdominal aorta: the Second Manifestations of Arterial Disease …
  717. Multi-modal magnetic resonance imaging quantifies atherosclerosis and vascular dysfunction in patients with type 2 diabetes mellitus
  718. Ventriculovascular coupling in systolic and diastolic heart failure
  719. Endothelial dysfunction: a contributor to adverse cardiovascular remodeling and heart failure development in type 2 diabetes beyond accelerated atherogenesis
  720. Aortic stiffness: current understanding and future directions
  721. Effets d’une prise unique de flavanols du cacao sur la réactivité vasculaire périphérique chez des patients atteints de diabète de type 2
  722. Pathogenesis and pathophysiology of diabetic nephropathy
  723. Determinants of increasing pulse pressure during 23 years’ follow‐up as a marker of arterial stiffness and vascular ageing
  724. The vascular endothelium in diabetes: a practical target fordrug treatment?
  725. Anti-atherosclerotic effects of sitagliptin in patients with type 2 diabetes mellitus
  726. Different role of wave reflection magnitude and timing on left ventricular mass reduction during antihypertensive treatment
  727. AGE and RAGE inhibitors in the treatment of diabetic retinopathy
  728. The Effects of Weight Gain and Atorvastatin Treatment on Arterial Stiffness
  729. Vascular stiffness: its measurement and significance for epidemiologic and outcome studies
  730. Impaired redox signaling and antioxidant gene expression in endothelial cells in diabetes: a role for mitochondria and the nuclear factor-E2-related factor 2-Kelch-like …
  731. The pathobiology of diabetic vascular complications—cardiovascular and kidney disease
  732. Regular exercise, hormone replacement therapy and the age-related decline in carotid arterial compliance in healthy women
  733. Aortic pulse wave velocity and albuminuria in patients with type 2 diabetes
  734. Vascular endothelial dysfunction in diabetic cardiomyopathy: pathogenesis and potential treatment targets
  735. The role of renin–angiotensin–aldosterone system inhibition in chronic kidney disease
  736. Risk stratification
  737. Arterial Stiffness and Coronary Ischemic
  738. Characteristics of arterial stiffness in very low birth weight premature infants
  739. MRI and echocardiographic assessment of the diastolic dysfunction of normal aging: altered LV pressure decline or load?
  740. Mechanisms of disease: the oxidative stress theory of diabetic neuropathy
  741. Walking may be related to less vascular stiffness in the Activity Counseling Trial (ACT)
  742. Associations of cardiovascular disease risk factors and calcified atherosclerosis with aortoiliac bifurcation position: the multiethnic study of atherosclerosis
  743. International Journal of Diabetes & Metabolic Disorders
  744. Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive …
  745. Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E–null mice
  746. Aortic correlates of clinical markers of large artery structure and function. Effects of aging and hypertension
  747. Obesity in a model of haploinsufficiency uncovers a causal role for lipid-derived aldehydes in human metabolic disease and cardiomyopathy
  748. Diabetic microangiopathy—etiopathogenesis, new possibilities in diagnostics and management
  749. Oxidative stress implication in retinal diseases—A review
  750. New approaches to the treatment of nephropathy in diabetes
  751. Distinct myocardial targets for diabetes therapy in heart failure with preserved or reduced ejection fraction
  752. Healthy lifestyle-based approaches for successful vascular aging
  753. Carotid stiffness indicates risk of ischemic stroke and TIA in patients with internal carotid artery stenosis: the SMART study
  754. All-extremity exercise training improves arterial stiffness in older adults
  755. Transforming growth factor β in hypertensives with cardiorenal damage
  756. Increased central artery stiffness in impaired glucose metabolism and type 2 diabetes: the Hoorn Study
  757. Premature coronary artery disease and arterial stiffness: too soon to speculate?
  758. 1.2. 4 Vascular remodelling
  759. Arterial stiffening as a possible risk factor for both atherosclerosis and diastolic heart failure
  760. Arterial aging: a review of the pathophysiology and potential for pharmacological intervention
  761. Arterial stiffness: a novel cardiovascular risk factor in kidney disease patients
  762. The role of arterial stiffness in stratifying the overall cardiovascular risk
  763. Atherosclerosis, arterial stiffness and antihypertensive drug therapy
  764. Estimated aortic stiffness is independently associated with cardiac baroreflex sensitivity in humans: role of ageing and habitual endurance exercise
  765. Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome
  766. Skin Autofluorescence Relates to Soluble Receptor for Advanced Glycation End-Products and Albuminuria in Diabetes Mellitus
  767. Interrelationship between diabetes mellitus and heart failure: The role of peroxisome proliferator-activated receptors in left ventricle performance
  768. Preclinical aortic atherosclerosis in adolescents with chronic disease
  769. Aortic correlates of clinical markers of large artery structure and function. Effects of aging and hypertension
  770. Differential Gene Transcription in Monocytes from Chronic Kidney Disease and Healthy Patients
  771. Imaging in diabetic cardiomyopathy
  772. SIRT1-DEPENDENT CYTOPROTECTIVE EFFECTS OF RESVERATROL IN HIGH GLUCOSE-CHALLENGED HUMAN ENDOTHELIAL CELLS INVOLVES …
  773. Central blood pressures: do we need them in the management of cardiovascular disease? Is it a feasible therapeutic target?
  774. Effect of unilateral resistance training on arterial compliance in elderly men
  775. Arterial Stiffness as a Cardiovascular Risk Factor for the Development of Preeclampsia and Pharmacopreventive Options
  776. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE
  777. AGEs induce oxidative stress and activate protein kinase C-βII in neonatal mesangial cells
  778. Heart failure with normal ejection fraction: consideration of mechanisms other than diastolic dysfunction
  779. Food-related carbonyl stress in cardiometabolic and cancer risk linked to unhealthy modern diet
  780. Endothelial Dysfunction in Diabetes: An Update on Mechanisms and Therapeutic Targets
  781. Cardiovascular calcifications in old age: mechanisms and clinical implications
  782. High ambient glucose augments angiotensin II-induced proinflammatory gene mRNA expression in human mesangial cells: effects of valsartan and simvastatin
  783. Arterial stiffness and systolic hypertension: determinants, assessment, and clinical consequences
  784. Advanced glycation end products, rage, and aging
  785. Noninvasive assessment of arterial stiffness and risk of atherosclerotic events
  786. Increased serum levels of advanced glycation endproducts predict total, cardiovascular and coronary mortality in women with type 2 diabetes: a population …
  787. New therapy approach in heart failure with preserved ejection fraction based on new pathophysiological concept
  788. Dynamic Changes in Myocardial Matrix and Relevance to Disease
  789. Glucose-and non-glucose-induced mitochondrial dysfunction in diabetic kidney disease
  790. Altered proximal aortic stiffness and endothelin plasma levels in diabetic patients with end-stage renal disease
  791. Elevated plasma B-type natriuretic peptide concentration and resistive index, but not decreased aortic distensibility, associate with impaired blood flow at popliteal …
  792. Nitric oxide regulates transforming growth factor-β signaling in endothelial cells
  793. The early life origins of vascular ageing and cardiovascular risk: the EVA syndrome
  794. Cardiology Research and Practice
  795. Arterial stiffness and hypertension in the elderly
  796. Dissociation of aortic pulse wave velocity with risk factors for cardiovascular disease other than hypertension: a systematic review
  797. Aortic pulse wave velocity improves cardiovascular event prediction: an individual participant meta-analysis of prospective observational data from 17,635 subjects
  798. Small artery remodeling in obesity and insulin resistance
  799. Arterial stiffness: A review in type 2 diabetes
  800. Oxidative stress-related mechanisms and antioxidant therapy in diabetic retinopathy
  801. Potential mechanisms underlying the association between type II diabetes mellitus and cognitive dysfunction in rats: a link between miRNA-21 and …
  802. Mechanics and function of the pulmonary vasculature: implications for pulmonary vascular disease and right ventricular function
  803. The effects of changes in the metabolic syndrome detection status on arterial stiffening: a prospective study
  804. Skin autofluorescence as a marker of cardiovascular risk in children with chronic kidney disease
  805. Novel pharmacological treatments for heart failure
  806. Relationship between upper and lower limb conduit artery vasodilator function in humans
  807. Women want the heavens, men want the earth
  808. Targeting Signaling Pathways
  809. Hypertension and chronic kidney disease: respective contribution of mean and pulse pressure and arterial stiffness
  810. Cardiovascular Disease in the Elderly
  811. Insulin resistance: the cardiovascular aspect
  812. Effects of 3-months sitting callisthenic balance and resistance exercise on aerobic capacity, aortic stiffness and body composition in healthy older participants …
  813. Systolic blood pressure response to exercise in type 1 diabetes families compared with healthy control individuals
  814. Hemoglobin A1c and arterial and ventricular stiffness in older adults
  815. Physical activity prevents age-related impairment in nitric oxide availability in elderly athletes
  816. Time-efficient physical training for enhancing cardiovascular function in midlife and older adults: promise and current research gaps
  817. Aging progressively impairs endothelium-dependent vasodilation in forearm resistance vessels of humans
  818. Hyperglycemia and endothelial dysfunction in atherosclerosis: lessons from type 1 diabetes
  819. Arterial stiffness and stroke in hypertension: therapeutic implications for stroke prevention
  820. Central blood pressure as a risk marker for cardiovascular complications
  821. Vascular and metabolic response to isolated small muscle mass exercise: effect of age
  822. Diabetic cardiovascular disease induced by oxidative stress
  823. Arterial stiffness
  824. Skin autofluorescence is associated with the progression of chronic kidney disease: a prospective observational study
  825. Vascular effects of diabetes mellitus
  826. Effect of exercise training and weight loss on arterial stiffness and pulsatile hemodynamics
  827. Central Blood Pressure Parameters Correlate with Cardiac Structure and Function in Healthy Chinese Individuals without Cardiovascular Disease
  828. Mechanisms Involved in Premature Aging in the Heart—Is There an Implication for Cardiac Surgery?
  829. Cardiovascular adaptations to exercise training in older women with and without type 2 diabetes mellitus
  830. Probiotic Supplementation, The Gut Microbiota, and Cardiovascular Health
  831. Left ventricular diastolic dysfunction in dialysis patients assessed by novel speckle tracking strain rate analysis: prevalence and determinants
  832. Diabetic cardiomyopathy: from the pathophysiology of the cardiac myocytes to current diagnosis and management strategies
  833. Effect of aging on metabolic pathways in endothelial progenitor cells
  834. Vascular Stem and Progenitor Cells in Diabetic Complications
  835. Neurodegeneration is dependant on microglial proximity and nitric oxide production
  836. Treatment of heart failure with normal ejection fraction: an inconvenient truth!
  837. Specific aspects of high blood pressure in the elderly
  838. Treatment of heart failure with preserved systolic function in the elderly
  839. Validation of carotid artery tonometry as a means of estimating augmentation index of ascending aortic pressure
  840. Novel therapies in heart failure
  841. Pulse wave analysis and diabetes mellitus. A systematic review.
  842. VASCULAR BIOLOGY-HEMODYNAMICS-HYPERTENSION Arterial stiffness in predialysis patients with uremia.
  843. Blood pressure and arterial load after transcatheter aortic valve replacement for aortic stenosis
  844. Heart failure in the elderly: advances and challenges
  845. Role of aging and aerobic fitness on large elastic artery stiffness, brain structure and cognitive performance in humans
  846. Renin-angiotensin-aldosterone system blockade in diabetic nephropathy. Present evidences
  847. The effects of strength training on arterial structure and function in middle-aged and older adults
  848. The effect of aerobic exercise on pulse wave velocity in middle-aged and elderly people: a systematic review and meta-analysis of randomized controlled …
  849. Lifetime risks for cardiovascular disease mortality by cardiorespiratory fitness levels measured at ages 45, 55, and 65 years in men: the Cooper Center Longitudinal …
  850. Dialysis initiation and clinical outcomes in chronic kidney disease: Role of education and biomarkers
  851. Cardiovascular dysfunction in experimental diabetes: effect of treatment with insulin and chromium
  852. Novel Treatments in Diabetic Nephropathy
  853. Advanced glycation end-products and outcome in heart failure patients with preserved and reduced ejection fraction
  854. Studies of vascular function in patients with heart failure and either preserved or reduced left ventricular systolic function
  855. Complimentary and personal copy for Mariko Takenokuchi, Kinuyo Matsumoto, Yuko Nitta, Rumi Takasugi, Yukari Inoue, Michi Iwai, Keiichi Kadoyama
  856. Interaction between mean arterial pressure and HbA1c in prediction of cardiovascular disease hospitalisation: a population-based case-control study
  857. The Arterial Pulse: Vascular Biology, Vascular Function Testing, and Therapies
  858. Age-associated changes in the cardiovascular system
  859. The vascular endothelium in diabetes—a therapeutic target?
  860. The future of antihypertensive treatment: from myth to imminent reality
  861. Is longitudinal pulse pressure a better predictor of 24-hour urinary albumin excretion than other indices of blood pressure?
  862. Role of increased aortic stiffness in the pathogenesis of heart failure
  863. Exercise and arterial adaptation in humans: uncoupling localized and systemic effects
  864. Use of pulse pressure method for estimating total arterial compliance in vivo
  865. Occasional Survey Arterial Stiffness in Children and Teenagers: An Emerging Cardiovascular Risk Factor
  866. Normal aging of the cardiovascular system
  867. Update on the treatment of diabetic retinopathy
  868. Effects of exercise modalities on arterial stiffness and wave reflection: a systematic review and meta-analysis of randomized controlled trials
  869. Preserved α-Adrenergic tone in the leg vascular bed of spinal cord–injured individuals
  870. Clinical studies of advanced glycation end product inhibitors and diabetic kidney disease
  871. The stroke volume/pulse pressure ratio predicts coronary heart disease mortality in a population of elderly men
  872. Dr. Russell S. Richardson Medical Teaching Facility 9500 Gilman Drive La Jolla, CA 92093-0623
  873. Effects of aging and exercise training on structural and vasoconstrictor properties of skeletal muscle arterioles
  874. The prevalence of preclinical atherosclerosis in a healthy adult population
  875. Therapeutic Advances in Cardiovascular Disease
  876. Diabetes mellitus and aorta: does size matter?
  877. Basic Mechanisms Mediating Cardiomyopathy and Heart Failure in Aging
  878. VU Research Portal
  879. Treatment of patients with heart failure and preserved ejection fraction
  880. Nonenzymatic glycosylation and the pathogenesis of diabetic complications
  881. Pulse pressure and risk for myocardial infarction and heart failure in the elderly
  882. The pulse pressure-to-stroke index ratio predicts cardiovascular events and death in uncomplicated hypertension
  883. Pulse Wave Velocity is an Independent Predictor of Office Hypertension
  884. The impact of the 24-h movement spectrum on vascular remodeling in older men and women: a review
  885. Diabetes and the Cardiovascular System
  886. Ambulatory monitoring of the cardiovascular system: the role of pulse wave velocity
  887. Arterial stiffness in diabetes and the metabolic syndrome: a pathway to cardiovascular disease
  888. Glycation, antiglycation, and deglycation: Their role in aging mechanisms and geroprotective effects (literature review)
  889. The Roles of Oxidative Stress, Inflammation and Adaptive Immunity in Aortic Stiffening
  890. The aging hypertensive heart: a brief update
  891. Mechanisms of kidney fibrosis and the role of antifibrotic therapies
  892. DF-5 compound delays development of diabetic nephropathy in rats
  893. Infarcted Rat Myocardium
  894. Measurement of advanced glycation end products in the skin using autofluorescence spectroscopy in patients with chronic kidney disease
  895. Vascular Rho-related BTB Domain-containing Protein 1 (RhoBTB1) in Hypertension and Aortic Stiffness
  896. AGEing and osteoarthritis: a different perspective
  897. A vessel age. Mechanisms of vessel wall ageing. Methods of assessment
  898. Immune modulation of vascular stiffening
  899. Accumulation of Advanced Glycation End Products, Measured by Skin Auto-fluorescence is Associated with Presence and Number of Diabetes Complications; …
  900. Coronary Microvascular Disease as an Early Culprit in
  901. Arterial rigidity and central pressure: novel aspects of pathophysiology and therapy
  902. Gene regulatory networks: modeling, intervention and context
  903. Aortic diameter, aortic stiffness, and wave reflection increase with age and isolated systolic hypertension
  904. Fructosamine 3-kinase and glyoxalase I polymorphisms and their association with soluble RAGE and adhesion molecules in diabetes
  905. Advanced glycoxidation: A new risk factor for cardiovascular disease?
  906. Pulse pressure partially explains the higher incidence of cardiovascular disease associated with advanced glycation endproducts and low-grade inflammation …
  907. Ab initio Study on Benzoin Condensation Catalysed by Alagebrium in order to Test for Alagebrium’s Potential as a Thiamine Supplement
  908. Molekulare Grundlagen altersspezifischer Erkrankungen des Herz-Kreislauf-Systems und der Arteriosklerose
  909. Aging and the Cardiovascular System
  910. Pulse Pressure and Diabetic Eye Disease
  911. Advances in the treatment of heart failure with a preserved ejection fraction
  912. Should pulse pressure influence prescribing?
  913. Arterial aging: a journey into subclinical arterial disease
  914. Correlates of Aortic Stiffness Progression in Patients With Type 2 Diabetes: Importance of Glycemic Control
  915. Novel therapies of diabetic nephropathy
  916. AGE-RAGE signalling in endothelial dysfunction and atherosclerosis in diabetes
  917. New methods of assessment of subclinical changes in the cardiovascular system in arterial hypertension
  918. Cardiovascular aging: the next frontier in cardiovascular prevention
  919. Vascular Biology of the metabolic syndrome
  920. 28 Diabetes, lipids and other cardiovascular risk factors
  921. Diabetes, pulse pressure and cardiovascular mortality: the Hoorn Study
  922. Hypertension management for the primary care clinician
  923. Cardiovascular changes with aging
  924. The pathogenesis of arterial stiffness and its prognostic value in essential hypertension and cardiovascular diseases
  925. The year in hypertension
  926. Impact of diabetes and hypertension on the heart
  927. Ventricular–vascular coupling in hypertension: methodological considerations and clinical implications
  928. Phlorizin exerts direct protective effects on palmitic acid (PA)-induced endothelial dysfunction by activating the PI3K/AKT/eNOS signaling pathway and …
  929. Cardiomyopathy and heart failure in aging
  930. Some mechanical aspects of arterial aging: physiological overview based on pulse wave analysis
  931. DISRUPTIONS OF ELASTIC ARTERIES PROPERTIES AND ENDOTHELIAL FUNCTION: MODERN METHODS FOR CORRECTION AND PREVENTION
  932. The Effect of Vitamin D3 Supplementation on Advanced Glycation End Products,(AGEs) And Soluble Receptor,(sRAGE) in African Americans and Hispanics with Type …
  933. Aging of the heart and arteries: relevance to cardiovascular disease
  934. Translational potential of high-resistance inspiratory muscle strength training
  935. Escape velocity: why the prospect of extreme human life extension matters now
  936. Systolic hypertension in the elderly: arterial wall mechanical properties and the renin–angiotensin–aldosterone system
  937. MANAGEMENT OF HYPERTENSION: NEW PERSPECTIVES
  938. Assessment of total cardiovascular risk in hypertensive subjects
  939. An analysis of the determinants of peripheral conduit arterial stiffness in children and teenagers in health and disease
  940. Glycosylation Inhibitors, PKC Inhibitors and Related Interventions Against Complications
  941. Role of the augmentation index in hypertension
  942. Arterial stiffness and the systolic hypertension syndrome
  943. Vascular aging: from molecular to clinical cardiology
  944. Diabetes and Advanced Glycoxidation End-Products
  945. Non-invasive measurements of arterial function: What? When? Why should we use them?
  946. Repurposing alagebrium for diabetic foot ulcer healing: Impact on AGEs/NFκB/NOX1 signaling
  947. Advanced glycation end products impair coronary artery BK channels via AMPK/Akt/FBXO32 signaling pathway
  948. Evidence that methylglyoxal and receptor for advanced glycation end products are implicated in bladder dysfunction of obese diabetic ob/ob mice
  949. Phyllanthus emblica L. extract alleviates leptin resistance and lipid accumulation by inhibiting methylglyoxal production
  950. RAGE signaling regulates the progression of diabetic complications
  951. Oxidative Stress in Health and Disease
  952. Advanced glycation end products: Key mediator and therapeutic target of cardiovascular complications in diabetes
  953. Effects of Zofenopril on Arterial Stiffness in Hypertension Patients
  954. The Role of Advanced Glycation End-Product Levels Measured by Skin Autofluorescence in the Development of Mitral Annular Calcification
  955. Effects of ALT-711 treatment on age-related cerebrovascular dysfunction and cognitive impairment in aged mice
  956. Obesity does not alter vascular function and handgrip exercise hemodynamics in middle-aged patients with hypertension
  957. Receptor for advanced glycation end‐products: Biological significance and imaging applications
  958. Receptors for Advanced Glycation End Products (RAGE): promising targets aiming at the treatment of neurodegenerative conditions
  959. Current understanding of structural and molecular changes in diabetic cardiomyopathy
  960. A Perspective on the Impact of Advanced Glycation End Products in the Progression of Diabetic Nephropathy
  961. Effects of aging and endurance exercise training on cardiorespiratory fitness and cardiac structure and function in healthy midlife and older women
  962. Emerging Therapy for Diabetic Cardiomyopathy: From Molecular Mechanism to Clinical Practice
  963. The vascular disease of diabetic kidney disease
  964. Glycation of LDL: AGEs, impact on lipoprotein function, and involvement in atherosclerosis
  965. Accumulation of advanced glycation end products in skin and increased vascular ageing in the general population: the Malmö Offspring Study
  966. Fluid-Structure Interactions of Peripheral Arteries Using a Coupled in silico and in vitro Approach
  967. Arterial Stiffness is Associated with False-Positive ST-Segment Depression in Supine Bicycle Exercise Stress Echocardiography
  968. Non-apoptotic programmed cell deaths in diabetic pulmonary dysfunction: the new side of advanced glycation end products
  969. Functioning and mechanisms of PTMs in renal diseases
  970. Cerebrovascular CO2 reactivity and dynamic cerebral autoregulation through the eighth decade of life and their implications for cognitive decline
  971. The effect of aerobic exercises on arterial stiffness in older people: A systematic review and meta-analysis
  972. Training the Vessels: Molecular and Clinical Effects of Exercise on Vascular Health—A Narrative Review
  973. A decade of aging in healthy older adults: longitudinal findings on cerebrovascular and cognitive health
  974. Estimation of central blood pressure waveform from femoral blood pressure waveform by blind sources separation
  975. Pathomechanisms of Diabetic Kidney Disease
  976. Effects of regular aerobic exercise on vascular function in overweight or obese older adults: A systematic review and meta-analysis
  977. Pathophysiology of NPH
Related Posts

Insulin & Cancer: How Insulin Literally Protects Cancer Cells From Being Killed

Pyrazines

Endocrine Disruptors

Mandatory FDA Disclaimer: Not intended to diagnose, treat, cure or prevent any disease.

Mandatory FDA Disclaimer: Not intended to diagnose, treat, cure or prevent any disease.

0
    0
    Your Cart
    Your cart is emptyReturn to Shop
    Continue Shopping